Updated daily
Drug recalls
Every FDA drug recall since 2004 - 18,109 enforcement reports, newest first, with what was recalled, why, the lots and the company. Class I is the most serious.
Class IIOngoingMay 3, 2023CBD Metered Dose InhalerMarketed Without an Approved NDA/ANDAWellness BioSciences · D-0541-2023Class IICompletedMay 3, 2023Pantoprazole sodium for Injection 40 mg*/vialCGMP Deviations; The impacted product and lot number was inadvertently placed into saleable inventory, which does not comply with approved procedures.Methapharm Inc · D-0540-2023Class IIOngoingApr 26, 2023Aripiprazole TabletsOut of specification (OOS) for Spectroscopic Identification test by IR.Ascend Laboratories, LLC · D-0539-2023Class IIOngoingApr 26, 2023C-Semaglutide 5mg/mL injectionLack of assurance of sterility.Pharmacy Plus, Inc. dba Vital Care Compounder · D-0538-2023Class IIOngoingApr 26, 2023Fast Acting Earwax Removal SystemCGMP Deviations: active ingredient may be subpotent before the labeled expiry due to degradation.Pharma Nobis LLC · D-0537-2023Class IITerminatedApr 26, 2023Verapamil Hydrochloride Extended-Release TabletsFailed Dissolution Specifications: Out of specification dissolution results above specified values.Amerisource Health Services LLC · D-0536-2023Class IIIOngoingApr 19, 2023Epinephrine Professional EMSLabeling; Incorrect NDC number on outer carton of product.Focus Health Group Inc · D-0535-2023Class IIIOngoingApr 19, 2023MEKTOVILabeling: Incorrect or Missing Lot and/or Exp Date: The carton and bottle labels state an expiry date of March 2026; the correct expiration date is February 2025.Pfizer Inc. · D-0532-2023Class IIITerminatedApr 19, 2023Bevacizumab 2.5 mg/0.1 mLLabeling: Incorrect or Missing Lot and/or Exp Date: Lot code on primary packaging is incorrect.Pine Pharmaceuticals, LLC · D-0531-2023Class IIOngoingApr 19, 2023Pantoprazole Sodium Delayed Release Tablets USP 40mgCGMP Deviations: DiscolorationHetero USA Inc · D-0530-2023Class IIITerminatedApr 19, 2023Norepinephrine Bitartrate InjectionFailed Impurities/Degradation Specifications: Above the specification limits yielded for related substance norepinephrine sulfonic acid impurity during routine product...Sun Pharmaceutical Industries Inc · D-0529-2023Class IIITerminatedApr 12, 2023Dodex Injectable Cyanocobalamin InjectionSub-potent drug: assay test result below specifications at 9-month timepoint.Accord Healthcare, Inc. · D-0528-2023Class IIOngoingApr 12, 2023Glimepiride Tablets USPcGMP Deviations for the manufacturing Firm (Accord Healthcare) after their inspection.Preferred Pharmaceuticals, Inc. · D-0527-2023Class IIOngoingApr 12, 2023Tadalafil TabletscGMP Deviations for the manufacturing Firm (Accord Healthcare) after their inspection.Preferred Pharmaceuticals, Inc. · D-0526-2023Class IIOngoingApr 12, 2023Simvastatin TabletscGMP Deviations for the manufacturing Firm (Accord Healthcare) after their inspection.Preferred Pharmaceuticals, Inc. · D-0525-2023Class IIOngoingApr 12, 2023Simvastatin TabletscGMP Deviations for the manufacturing Firm (Accord Healthcare) after their inspection.Preferred Pharmaceuticals, Inc. · D-0524-2023Class IIOngoingApr 12, 2023Simvastatin TabletscGMP Deviations for the manufacturing Firm (Accord Healthcare) after their inspection.Preferred Pharmaceuticals, Inc. · D-0523-2023Class IIOngoingApr 12, 2023Simvastatin TabletscGMP Deviations for the manufacturing Firm (Accord Healthcare) after their inspection.Preferred Pharmaceuticals, Inc. · D-0522-2023Class IIOngoingApr 12, 2023Pravastatin Sodium TabletscGMP Deviations for the manufacturing Firm (Accord Healthcare) after their inspection.Preferred Pharmaceuticals, Inc. · D-0521-2023Class IIOngoingApr 12, 2023Rosuvastatin TabletscGMP Deviations for the manufacturing Firm (Accord Healthcare) after their inspection.Preferred Pharmaceuticals, Inc. · D-0520-2023Class IIOngoingApr 12, 2023Rosuvastatin TabletscGMP Deviations for the manufacturing Firm (Accord Healthcare) after their inspection.Preferred Pharmaceuticals, Inc. · D-0519-2023Class IIOngoingApr 12, 2023Montelukast Sodium TabletscGMP Deviations for the manufacturing Firm (Accord Healthcare) after their inspection.Preferred Pharmaceuticals, Inc. · D-0518-2023Class IIOngoingApr 12, 2023Glimepiride TabletscGMP Deviations for the manufacturing Firm (Accord Healthcare) after their inspection.Preferred Pharmaceuticals, Inc. · D-0517-2023Class IIOngoingApr 12, 2023Finasteride TabletscGMP Deviations for the manufacturing Firm (Accord Healthcare) after their inspection.Preferred Pharmaceuticals, Inc. · D-0516-2023Class IIOngoingApr 12, 2023Doxazosin TabletscGMP Deviations for the manufacturing Firm (Accord Healthcare) after their inspection.Preferred Pharmaceuticals, Inc. · D-0515-2023Class IIOngoingApr 12, 2023Doxazosin TabletscGMP Deviations for the manufacturing Firm (Accord Healthcare) after their inspection.Preferred Pharmaceuticals, Inc. · D-0514-2023Class IIOngoingApr 12, 2023Clopidogrel Tablets USPcGMP Deviations for the manufacturing Firm (Accord Healthcare) after their inspection.Preferred Pharmaceuticals, Inc. · D-0513-2023Class IIOngoingApr 12, 2023Atorvastatin Calcium TabletscGMP Deviations for the manufacturing Firm (Accord Healthcare) after their inspection.Preferred Pharmaceuticals, Inc. · D-0512-2023Class IIOngoingApr 12, 2023Atorvastatin Calcium TabletscGMP Deviations for the manufacturing Firm (Accord Healthcare) after their inspection.Preferred Pharmaceuticals, Inc. · D-0511-2023Class IIITerminatedApr 12, 2023Montelukast Sodium Oral Granules USPFailed Impurities/Degradation Specifications: failed impurities for Sulphoxide and Impurity A.Teva Pharmaceuticals USA Inc · D-0510-2023Class IIOngoingApr 12, 2023Alprazolam C-IVCGMP Deviations: Repackaging firm recalling due to potential product cross contamination concerns at the manufacturer.Direct Rx · D-0509-2023Class IIOngoingApr 12, 2023Alprazolam C-IVCGMP Deviations: Repackaging firm recalling due to potential product cross contamination concerns at the manufacturer.Direct Rx · D-0508-2023Class IIOngoingApr 12, 2023Alprazolam C-IVCGMP Deviations: Repackaging firm recalling due to potential product cross contamination concerns at the manufacturer.Direct Rx · D-0507-2023Class IITerminatedApr 12, 2023Alprazolam TabCGMP Deviations: Downstream recall from Breckenridge Pharmaceuticals, Inc due to potential risk of Cross Contamination.Preferred Pharmaceuticals, Inc. · D-0506-2023Class IITerminatedApr 12, 2023Alprazolam TabCGMP Deviations: Downstream recall from Breckenridge Pharmaceuticals, Inc due to potential risk of Cross Contamination.Preferred Pharmaceuticals, Inc. · D-0505-2023Class IITerminatedApr 12, 2023Alprazolam TabCGMP Deviations: Downstream recall from Breckenridge Pharmaceuticals, Inc due to potential risk of Cross Contamination.Preferred Pharmaceuticals, Inc. · D-0504-2023Class IITerminatedApr 12, 2023Simvastatin 40 mg tabletscGMP DeviationsRemedyRepack Inc. · D-0503-2023Class IITerminatedApr 12, 2023Rosuvastatin 40mg tabletscGMP DeviationsRemedyRepack Inc. · D-0502-2023Class IITerminatedApr 12, 2023Rosuvastatin 10mg tabletscGMP DeviationsRemedyRepack Inc. · D-0501-2023Class IITerminatedApr 12, 2023Rosuvastatin 5mg tabletscGMP DeviationsRemedyRepack Inc. · D-0500-2023